Equities analysts expect that Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) will report earnings of ($0.94) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.98) and the highest estimate coming in at ($0.88). Esperion Therapeutics reported earnings per share of ($1.67) during the same quarter last year, which would indicate a positive year-over-year growth rate of 43.7%. The company is expected to announce its next earnings report on Monday, January 1st.
On average, analysts expect that Esperion Therapeutics will report full year earnings of ($3.70) per share for the current financial year, with EPS estimates ranging from ($3.94) to ($3.36). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.07) per share, with EPS estimates ranging from ($3.10) to $0.02. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.11. The firm had revenue of $18.84 million during the quarter, compared to analyst estimates of $15.41 million. The firm’s revenue for the quarter was up 136.1% on a year-over-year basis. During the same period in the prior year, the company posted ($3.50) earnings per share.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Deep Track Capital LP bought a new stake in Esperion Therapeutics in the fourth quarter valued at about $28,208,000. Deerfield Management Company L.P. Series C bought a new position in shares of Esperion Therapeutics in the fourth quarter valued at $25,000,000. Wasatch Advisors Inc. raised its stake in Esperion Therapeutics by 95.0% during the 4th quarter. Wasatch Advisors Inc. now owns 6,386,263 shares of the biopharmaceutical company’s stock valued at $31,931,000 after purchasing an additional 3,111,903 shares during the period. Altium Capital Management LP acquired a new stake in Esperion Therapeutics during the 4th quarter valued at $12,579,000. Finally, Meditor Group Ltd raised its stake in Esperion Therapeutics by 58.5% during the 4th quarter. Meditor Group Ltd now owns 4,468,835 shares of the biopharmaceutical company’s stock valued at $22,344,000 after purchasing an additional 1,650,000 shares during the period.
ESPR stock traded down $0.61 during mid-day trading on Friday, reaching $5.51. 2,033,702 shares of the company’s stock were exchanged, compared to its average volume of 1,308,733. The company has a market cap of $347.19 million, a price-to-earnings ratio of -0.79 and a beta of 0.43. The stock’s 50 day moving average is $5.15 and its 200 day moving average is $5.63. Esperion Therapeutics has a 12-month low of $3.28 and a 12-month high of $26.77.
Esperion Therapeutics Company Profile (Get Rating)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.